Dr Reddy's Laboratories Limited

Dr Reddy's may underperform on growth, margin worries after muted Q1

North America weakness, lower margins, uncertainty over key launches weigh on earnings outlook

Dr Reddy's Labs shares tank 9% to 52-week low after Q1 show. Time to sell?

Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Dr Reddy's Foundation targets 100k soil samples ahead of rabi season

Dr Reddy's Foundation -- a family-owned trust and one of the key beneficiaries of the CSR funds of pharma major Dr Reddy's Laboratories -- is scaling up operations at its Hyderabad soil testing facility with the lab targeting between 75,000 and 1,00,000 samples ahead of the next Rabi season -- more than double what it processed in its first full year of operations. The move comes amid growing concern over depleting soil health and implementation gaps in the Centre's Soil Health Card scheme rolled out nationally in 2015. "Though the government's soil testing ecosystem exists, the scale of the problem is huge. So we decided to address this issue in our own way," said Suman Saraswathibatla, Director (Rural Livelihoods and Climate Action) at the foundation. This soil testing facility is central to the Foundation's broader soil health and regenerative agriculture programme, under which assessing soil condition is treated as the starting point for any intervention. The push for an in-hou

Dr Reddy's plunges 6% on semaglutide batch quality, supply delay concerns

Dr Reddy's informed stock exchanges that certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient used in the product.

Dr Reddys gains over 4%; hits 52-week high on near 3X jump in volume

Dr Reddys Laboratories stock hit a fresh 52-week high of ₹1,410 in Monday's intra-day trade, backed by strong surge in trading volume.

Patent expiry: A $5 bn opportunity for Indian pharma majors, says report

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

Dr Reddy's Laboratories launches generic Semaglutide injection in Canada

Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. "The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said. He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. "As GLP-1

Wegovy copycat to be priced competitively with 50-60% discounts: Dr Reddy's

Wegovy's monthly price in India ranges from ₹10,850 ($119.65) for the lowest 0.25 mg dose to ₹16,400 for the highest 2.4 mg dose

Dr Reddy's: 5 technical reasons why Choice Broking is bullish on this stock

Analysts at Choice Broking expects Dr Reddy's Laboratories stock to gain up to 15.5%, and test ₹1,465 levels on the upside in the medium-term given the favourable structure on the weekly chart.

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

DRL semaglutide ruling may set precedent for generic makers: Experts

Ruling enables production for non-patented markets but bars India sales till 2026; experts say it may shape future drug access cases

Why did Dr Reddy's share rise over 2% in overall subdued market? Details

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Dr Reddy's gets EU nod for drug used to treat bone-weakening conditions

The European Commission's approval allows Dr Reddy's to market AVT03 across the European Union and European Economic Area for treating conditions that cause bone weakening

Dr Reddy's plunges 6%, hits 5-month low; why pharma stock under pressure?

Dr Reddy's Laboratories has received a Notice of Non-Compliance from Pharmaceutical Drugs Directorate, Canada, regarding its Abbreviated New Drug Submission for Semaglutide Injection.

New launch traction for Dr Reddy's key to offsetting price erosion

Given that price erosion in the North American market is expected to continue in the near term, some brokerages have cut their earnings estimates for the stock

Stocks to Watch today: RIL, Dr Reddy's Labs, Coforge, Hudco, Container Corp

Stocks to Watch Today, Monday, October 27, 2025: Reliance Industries, Container Corporation of India, PTC Industries, Mazagon Dock Shipbuilders, and Indian Oil are among the top stocks to watch today

Dr Reddy's Q2FY26 results: Profit up 14% at ₹1,437.2 cr, revenue jumps 10%

Dr Reddy's Ebitda for the quarter stood at ₹2,351.1 crore, up 3 per cent Y-o-Y and sequentially, with an Ebitda margin of 26.7 per cent

Q2 results today: Dr Reddy's Labs, ITC Hotels, NACL Industries on Oct 24

Aditya Birla Sun Life AMC, SBI Life Insurance Company, SBI Cards and Payment Services, India Radiators, and Sigachi Industries will also release their September quarter earnings reports today

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.